Life sciences, Hematology and oncology

★Absolute Lymphocyte Counts after Lenalidomide Initiation May Predict the Prognosis of Patients with Relapsed or Refractory Multiple Myeloma.
Nakagawa; Masaru; Noriyoshi Iriyama; Takuto Ishikawa; Katsuhiro Miura; Yoshihito Uchino; Hiromichi Takahashi; Takashi Hamada; Kazuhide Iizuka; Takashi Koike; Kazuya Kurihara; Tomohiro Nakayama; Yoshihiro Hatta; and Masami Takei
Cancer Diagnosis & Prognosis, Jul. 2021, Refereed, Not invited
Lead

Pulmonary Veno-Occlusive Disease after Autologous Stem Cell Transplantation.
Takashi Hamada; Hiromichi Takahashi; Masaru Nakagawa; Hironao Nukariya; Shun Ito; Toshihide Endo; Kazuya Kurihara; Takashi Koike; Kazuhide Iizuka; Shimon Ohtake; Takashi Ichinohe; Toshiya Maebayashi; Katsuhiro Miura; Yoshihiro Hatta; Hideki Nakamura
Case reports in oncology, 2023

Pirarubicin-based intensive chemotherapy followed by consolidative high-dose chemotherapies for peripheral T-cell lymphomas: A noncomparative phase 2 study
Takahashi H; Miura K; Nakagawa M; Nishimaki H; Ito S; Nukariya H; Kurihara K; Endo T; Koike T; Hamada T; Iizuka K; Ohatake S; Iriyama N; Nakayama T; Masuda S; Hatta Y; Nakamura H
Hematological Oncology, Jul. 2022, Refereed, Not invited

Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma
Miura K; Takahashi H; Nakagawa M; Hamada T; Uchino Y; Iizuka K; Ohtake S; Iriyama N; Hatta Y; Nakamura H
Expert Review of Anticancer Therapy, Jun. 2022, Refereed, Invited

Clinical impact of central nervous system-directed therapies on intravascular large B-cell lymphoma: A single institution's experience.
Takahashi H; Nishimaki H; Nakanishi Y; Hamada T; Nakagawa M; Iizuka K; Uchino Y; Iriyama N; Miura K; Nakayama T; Masuda S; Hatta Y; Nakamura H
eJHaem, Feb. 2022, Refereed, Not invited

UVC disinfects SARS‑CoV‑2 by induction of viral genome damage without apparent efects on viral morphology and proteins
Chieh‑Wen Lo; Ryosuke Matsuura; Kazuki Iimura; Satoshi Wada; Atsushi Shinjo; Yoshimi Benno; Masaru Nakagawa; Masami Takei; and YokoAida
scientific reports, Jul. 2021, Refereed, Not invited

Impact of CD56 Continuously Recognizable as Prognostic Value of Acute Promyelocytic Leukemia: Results of Multivariate Analyses in the Japan Adult Leukemia Study Group (JALSG)-APL204 Study and a Review of the Literature
Takeshita A; Asou N; Atsuta Y; Furumaki H; Sakura T; Ueda Y; Sawa M; Dobashi N; Taniguchi Y; Suzuki R; Nakagawa M; Tamaki S; Hagihara M; Fujimaki K; Minamiguchi H; Fujita H; Yanada M; Maeda Y; Usui N; Kobayashi Y; Kiyoi H; Ohtake S; Matsumura I; Naoe T; Miyazaki Y; Group TJALS.
Cancers (Basel), Jun. 2020, Refereed, Not invited

Increased Arbekacin Clearance in Patients With Febrile Neutropenia.
Takahiro Nakayama; Masayuki Chuma; Naohiro Tochikura; So Iwabuchi; Shinichiro Suzuki; Chiaki Matsumoto; Toru Imai; Takashi Hamada; Masaru Nakagawa; Hiromichi Takahashi; Yoshihito Uchino; Katsuhiro Miura; Noriyoshi Iriyama; Yoshihiro Hatta; Masami Takei; Takahisa Kimura
Therapeutic drug monitoring, Feb. 2020, Refereed, Not invited

MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy.
Kazuya Kurihara; Noriyoshi Iriyama; Katsuhiro Miura; Yoshihito Uchino; Hiromichi Takahashi; Masaru Nakagawa; Kazuhide Iizuka; Takashi Hamada; Takashi Koike; Yoshihiro Hatta; Tomohiro Nakayama; Masami Takei
Medical oncology (Northwood, London, England), Jul. 2019, Refereed, Not invited

A novel fusion gene involving PDGFRB and GCC2 in a chronic eosinophilic leukemia patient harboring t(2;5)(q37;q31).
Noriyoshi Iriyama; Hiromichi Takahashi; Hiromu Naruse; Katsuhiro Miura; Yoshihito Uchino; Masaru Nakagawa; Kazuhide Iizuka; Takashi Hamada; Yoshihiro Hatta; Tomohiro Nakayama; Masami Takei
Molecular genetics & genomic medicine, Apr. 2019, Refereed, Not invited

Thrombopoietin Levels During Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia.
Takashi Hamada; Noriyoshi Iriyama; Hiromichi Takahashi; Katsuhiro Miura; Yoshihito Uchino; Masaru Nakagawa; Yoshihiro Hatta; Masami Takei
Clinical drug investigation, Sep. 2018, Refereed, Not invited

Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study.
Takeshita A; Asou N; Atsuta Y; Sakura T; Ueda Y; Sawa M; Dobashi N; Taniguchi Y; Suzuki R; Nakagawa M; Tamaki S; Hagihara M; Fujimaki K; Furumaki H; Obata Y; Fujita H; Yanada M; Maeda Y; Usui N; Kobayashi Y; Kiyoi H; Ohtake S; Matsumura I; Naoe T; Miyazaki Y; and the Japanese Adult Leukemia Study Group
Leukemia, Aug. 2018, Refereed, Not invited

One percent chlorhexidine-alcohol for preventing central venous catheter-related infection during intensive chemotherapy for patients with haematologic malignancies.
Shimon Ohtake; Hiromichi Takahashi; Masaru Nakagawa; Yoshihito Uchino; Katsuhiro Miura; Noriyoshi Iriyama; Tomohiro Nakayama; Yoshihiro Hatta; Masami Takei
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, Jul. 2018, Refereed, Not invited

Enhanced perforin expression associated with dasatinib therapy in natural killer cells.
Noriyoshi Iriyama; Hiromichi Takahashi; Katsuhiro Miura; Yoshihito Uchino; Masaru Nakagawa; Yoshihiro Hatta; Masami Takei
Leukemia research, May 2018, Refereed, Not invited

Combined treatment with benzo[a]pyrene and 1α,25-dihydroxyvitamin D3 induces expression of plasminogen activator inhibitor 1 in monocyte/macrophage-derived cells.
Masaru Nakagawa; Shigeyuki Uno; Noriyoshi Iriyama; Manabu Matsunawa; Makoto Makishima; Jin Takeuchi; Isao Tsuboi; Yoshihiro Hatta; Masami Takei
Toxicology and Applied Pharmacology, Mar. 2018, Refereed, Not invited
Lead

[Achievement of a stringent complete response with low-dose pomalidomide monotherapy in a multiple myeloma patient].
Toshihide Endo; Takashi Hamada; Shimon Otake; Masaru Nakagawa; Yshihito Uchino; Hiromichi Takahashi; Katsuhiro Miura; Noriyoshi Iriyama; Takashi Koike; Kazuya Kurihara; Hiroko Sato; Yoshihiro Hatta; Msamai Takei
[Rinsho ketsueki] The Japanese journal of clinical hematology, 2018

Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib.
Noriyoshi Iriyama; Katsuhiro Miura; Yoshihiro Hatta; Sumiko Kobayashi; Yoshihito Uchino; Daisuke Kurita; Hitomi Sakagami; Hiromichi Takahashi; Masashi Sakagami; Yujin Kobayashi; Masaru Nakagawa; Shimon Ohtake; Yoshikazu Iizuka; Masami Takei
Oncology letters, May 2017, Refereed, Not invited

A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas.
Tatsuya Hayama; Katsuhiro Miura; Akihiro Uchiike; Masaru Nakagawa; Daisuke Tsutsumi; Masashi Sakagami; Yoshikazu Yoshida; Masami Takei
International journal of clinical pharmacy, Apr. 2017, Refereed, Not invited

Plasma cell maturity as a predictor of prognosis in multiple myeloma.
Noriyoshi Iriyama; Katsuhiro Miura; Yoshihiro Hatta; Yoshihito Uchino; Daisuke Kurita; Hiromichi Takahashi; Hitomi Sakagami; Masashi Sakagami; Yujin Kobayashi; Masaru Nakagawa; Shimon Ohtake; Yoshikazu Iizuka; Masami Takei
Medical oncology (Northwood, London, England), Aug. 2016

Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy
Katsuhiro Miura; Hiromichi Takahashi; Masaru Nakagawa; Asami Izu; Masahiko Sugitani; Daisuke Kurita; Masashi Sakagami; Shimon Ohtake; Yoshihito Uchino; Atsuko Hojo; Hitomi Kodaira; Mai Yagi; Yujin Kobayashi; Noriyoshi Iriyama; Sumiko Kobayashi; Satomi Kiso; Yukio Hirabayashi; Yoshihiro Hatta; Masami Takei
LEUKEMIA & LYMPHOMA, Jun. 2016, Refereed, Not invited

Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy
Hiromichi Takahashi; Katsuhiro Miura; Masaru Nakagawa; Masahiko Sugitani; Yusuke Amano; Daisuke Kurita; Masashi Sakagami; Shimon Ohtake; Yoshihito Uchino; Hitomi Kodaira; Noriyoshi Iriyama; Sumiko Kobayashi; Atsuko Hojo; Yujin Kobayashi; Yukio Hirabayashi; Machiko Kusuda; Yoshihiro Hatta; Tomohiro Nakayama; Masami Takei
Leukemia & Lymphoma, Mar. 2016, Refereed, Not invited

Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies.
Katsuhiro Miura; Masaru Nakagawa; Hiromichi Takahashi; Yoshihito Uchino; Hitomi Kodaira; Noriyoshi Iriyama; Masashi Sakagami; Shimon Ohtake; Sumiko Kobayashi; Atsuko Hojo; Daisuke Kurita; Yujin Kobayashi; Machiko Kusuda; Yukio Hirabayashi; Yoshihiro Hatta; Masami Takei
International journal of hematology, Mar. 2016

Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.
Daisuke Kurita; Katsuhiro Miura; Masaru Nakagawa; Shimon Ohtake; Masashi Sakagami; Yoshihito Uchino; Hiromichi Takahashi; Satomi Kiso; Atsuko Hojo; Hitomi Kodaira; Mai Yagi; Yukio Hirabayashi; Yujin Kobayashi; Noriyoshi Iriyama; Sumiko Kobayashi; Yoshihiro Hatta; Yoshimasa Kura; Masahiko Sugitani; Masami Takei
International journal of hematology, Jun. 2015

Induced Differentiation of Human Myeloid Leukemia Cells into M2 Macrophages by Combined Treatment with Retinoic Acid and 1 alpha,25-Dihydroxyvitamin D-3
Hiromichi Takahashi; Yoshihiro Hatta; Noriyoshi Iriyama; Yuichiro Hasegawa; Hikaru Uchida; Masaru Nakagawa; Makoto Makishima; Jin Takeuchi; Masami Takei
PLOS ONE, Nov. 2014, Refereed, Not invited

Safety and efficacy of high-dose cyclophosphamide, etoposide and ranimustine regimen followed by autologous peripheral blood stem cell transplant for patients with diffuse large B-cell lymphoma
Yujin Kobayashi; Yoshihiro Hatta; Masahiko Sugitani; Atsuko Hojo; Masaru Nakagawa; Machiko Kusuda; Yoshihito Uchino; Hiromichi Takahashi; Satomi Kiso; Yukio Hirabayashi; Mai Yagi; Hitomi Kodaira; Daisuke Kurita; Katsuhiro Miura; Noriyoshi Iriyama; Sumiko Kobayashi; Yoshimasa Kura; Akira Horikoshi; Umihiko Sawada; Jin Takeuchi; Masami Takei
Leukemia & Lymphoma, Feb. 2014, Refereed, Not invited

Clinical Significance of Co-Expression of MYC and BCL2 Protein in Advanced Diffuse Large B-Cell Lymphoma Treated with a Dose-Intensified Immunochemotherapy
Hiromichi Takahashi; Sumiko Kobayashi; Katsuhiro Miura; Daisuke Kurita; Yoshihiro Hatta; Masahiko Sugitani; Shimon Otake; Masaru Nakagawa; Masashi Sakagami; Yoshihito Uchino; Hitomi Kodaira; Noriyoshi Iriyama; Machiko Kusuda; Atsuko Hojo; Mai Yagi; Yukio Hirabayashi; Yujin Kobayashi; Tomohiro Nakayama; Masami Takei
BLOOD, Dec. 2015, Not refereed, Not invited

The impact of undernutrition on adherence to R-CHOP therapy in elderly patients with DLBCL
Nakagawa M; Miura K; Kurihara K; Endo T; Koike T; Hamada T; Iizuka K; Takahashi H; Uchino Y; Iriyama N; Hatta Y; Takei M
第18回日本臨床腫瘍学会学術集会, Feb. 2021, Not invited

未治療進行期末梢性T細胞リンパ腫へのdouble-THP-COP療法と大量化学療法による地固め療法
Takahashi H; Miura K; Nakagawa M; Uchino Y; Ito S; Nukariya H; Kurihara K; Endo T; Koike T; Hamada T; Iizuka K; Iriyama N; Hatta Y; Nakayama T; Takei M
第82回日本血液学会学術集会, Oct. 2020, Not invited

高齢者アグレッシブリンパ腫に対する外来初回化学療法の安全性―単一施設における12症例の検討―
36.Kobayashi T; Miura K; Uchino Y; Takahashi H; Nakagawa M; Iizuka K; Hamada T; Koike T; Kurihara K; Endo T; Ito S; Nukariya H; Hatta Y; Nakayama T; Takei M
第82回日本血液学会学術集会, Oct. 2020, Not invited

初発の移植非適応多発性骨髄腫患者に対するボルテゾミブ維持療法の有効性の検討
Noguchi Y; Iriyama N; Miura K; Uchino Y; Takahashi H; Nakagawa M; Iizuka K; Hamada T; Koike T; Kurihara K; Endo T; Ito S; Nukariya H; Hatta Y; Nakayama T; Takei M
第82回日本血液学会学術集会, Oct. 2020, Not invited

新規治療薬時代の多発性骨髄腫患者におけるCD19発現の臨床的意義の検討
Ito S; Iriyama N; Miura K; Uchino Y; Takahashi H; Nakagawa M; Iizuka K; Hamada T; Koike T; Kurihara K; Endo T; Nukariya H; Hatta Y; Nakayama T; Takei M
第82回日本血液学会学術集会, Oct. 2020, Not invited

新規治療薬時代以降に診断された多発性骨髄腫患者における時代別の治療モダリティーと予後の解析
Yoshida T; Iriyama N; Miura K; Uchino Y; Takahashi H; Nakagawa M; Iizuka K; Hamada T; Koike T; Kurihara K; Endo T; Ito S; Nukariya H; Hatta Y; Nakayama T; Takei M
第82回日本血液学会学術集会, Oct. 2020, Not invited

多発性骨髄腫患者においてレナリドミド療法開始後のリンパ球数は治療アウトカムに影響する
石川 拓斗; 入山 規良; 中川 優; 三浦 勝浩; 内野 慶人; 高橋 宏通; 濱田 高志; 飯塚 和秀; 小池 隆; 栗原 一也; 野口 篤人; 飯塚 芳一; 八田 善弘; 中山 智祥; 武井 正美
第81回日本血液学会学術集会, Oct. 2019, Not invited

JAK2アレルバーデンの高い患者は血小板コントロールが良好でもvWF活性低値のリスクが高い
飯塚 和秀; 入山 規良; 森下 総司; 三浦 勝浩; 飯塚 芳一; 西崎 祐史; 柳澤 尚武; 安藤 純; 内野 慶人; 高橋 宏通; 中川 優; 濱田 高志; 八田 善弘; 中山 智祥; 武井 正美; 小松 則夫
第81回日本血液学会学術集会, Oct. 2019, Not invited

AYA世代発症の血液疾患に対する移植関連合併症
伊東 正剛; 内野 慶人; 濱田 高志; 植野 優; 中原 衣里菜; 飯塚 和秀; 中川 優; 金澤 剛二; 高橋 宏通; 平井 麻衣子; 三浦 勝浩; 入山 規良; 谷ヶ崎 博; 陳 基明; 八田 善弘; 森岡 一朗; 武井 正美
第81回日本血液学会学術集会, Oct. 2019, Not invited

多発性骨髄腫において新規薬剤導入以降の治療の多様化は患者生存率をより改善する
野口 篤人; 入山 規良; 中川 優; 三浦 勝浩; 内野 慶人; 高橋 宏通; 濱田 高志; 飯塚 和秀; 小池 隆; 栗原 一也; 石川 拓斗; 飯塚 芳一; 八田 善弘; 中山 智祥; 武井 正美
第81回日本血液学会学術集会, Oct. 2019, Not invited

当院でELdを施行した再発・難治性多発性骨髄腫9例の検討
濱田 高志; 入山 規良; 中川 優; 三浦 勝浩; 内野 慶人; 高橋 宏通; 飯塚 和秀; 小池 隆; 栗原 一也; 飯塚 芳一; 八田 善弘; 武井 正美
第81回日本血液学会学術集会, Oct. 2019, Not invited

Lymphocyte counts 3 months after lenalidomide initiation may affect the prognosis of patients with RRMM
Masaru Nakagawa; Noriyoshi Iriyama; Yoshihito Uchino; Katsuhiro Miura; Hiromichi Takahashi; Takashi Hamada; Yoshihiro Hatta; Masami Takei
第80回日本血液学会学術集会, Oct. 2018, Not invited

日本内科学会

日本血液学会

日本臨床腫瘍学会

日本骨髄腫学会